July 31, 2024

HEMGENIX Has Been Administered Across The U.S.

Administered in Green Bay

HEMGENIX is revolutionizing treatment with its groundbreaking one-time infusion that offers elevated and sustained factor IX levels for years. Approved by the FDA in 2022, HEMGENIX has been the focus of extensive research for many years, promising new hope for patients.

We are thrilled to highlight a significant achievement within our team. Andrea Buxton, APNP, one of HOC’s Nurse Practitioners, recently shared her invaluable insights on the preparation and administration experiences for the first two patients to be commercially dosed with HEMGENIX. Her contributions are not only a testament to her expertise but also underscore the innovative spirit that drives our organization.

For more information check out the FAQ’s from HEMGENIX website:

.

 

Recent Posts

Aging with Bleeding Disorders: Senior Care Tips and Considerations

Understanding the Challenges of Aging with Bleeding Disorders The Impact of Aging on Bleeding DisordersAs individuals with bleeding disorders age, they may face unique challenges that require tailored care. Factors such as joint health deterioration, increased risk of...

Exploring Health Literacy and Resilience with Dr. Bridget Freeman

Today on Beyond the Bleeds, we welcome Dr. Bridget Freeman to discuss the essential elements of comprehensive health outcomes. We dive into the multifaceted approaches required to ensure long-lasting health improvements, encompassing agriculture, child education,...

Social Media